Literature DB >> 17220176

Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium.

Shabaz A Hamid1, Hugo S Bower, Gary F Baxter.   

Abstract

Intracellular signal transduction events in reperfusion following ischemia influence myocardial infarct development. Here we investigate the role of Rho kinase (ROCK) activation as a specific injury signal during reperfusion via attenuation of the reperfusion injury salvage kinase (RISK) pathway phosphatidylinositol 3-kinase (PI3K)/Akt/endothelial nitric oxide (NO) synthase (eNOS). Rat isolated hearts underwent 35 min of left coronary artery occlusion and 120 min of reperfusion. Phosphorylation of the ROCK substrate protein complex ezrin-radixin-moesin, assessed by immunoblotting and immunofluorescence, was used as a marker of ROCK activation. Infarct size was determined by tetrazolium staining, and terminal dUTP nick-end labeling (TUNEL) positivity was used as an index of apoptosis. The ROCK inhibitors fasudil or Y-27632 given 10 min before ischemia until 10 min after reperfusion reduced infarct size (control, 34.1 +/- 3.8%; 5 microM fasudil, 18.2 +/- 3.1%; 0.3 microM Y-27632, 19.4 +/- 4.4%; 5 microM Y-27632, 9.2 +/- 2.9%). When 5 microM Y-27632 was targeted specifically during early reperfusion, robust infarct limitation was observed (14.2 +/- 2.6% vs. control 33.4 +/- 4.4%, P<0.01). The protective action of Y-27632 given at reperfusion was attenuated by wortmannin (29.2 +/- 6.1%) and N(omega)-nitro-L-arginine methyl ester (30.4 +/- 5.7%), confirming a protective mechanism involving PI3K/Akt/NO. Ezrin-radixin-moesin phosphorylation in risk zone myocardium confirmed early and sustained ROCK activation during reperfusion and its inhibition by Y-27632. Inhibition of ROCK activation at reperfusion reduced the proportion of TUNEL-positive nuclei in the infarcted region. In conclusion, ROCK activation occurs specifically during early reperfusion. Inhibition of ROCK at reperfusion onset limits infarct size through an Akt/eNOS-dependent mechanism, suggesting that ROCK activation at reperfusion may be deleterious through suppression of the RISK pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17220176     DOI: 10.1152/ajpheart.01393.2006

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  47 in total

Review 1.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

2.  Rho-kinase signalling regulates CXC chemokine formation and leukocyte recruitment in colonic ischemia-reperfusion.

Authors:  Stefan Santen; Yusheng Wang; Matthias W Laschke; Michael D Menger; Bengt Jeppsson; Henrik Thorlacius
Journal:  Int J Colorectal Dis       Date:  2010-07-01       Impact factor: 2.571

Review 3.  Rho kinase proteins--pleiotropic modulators of cell survival and apoptosis.

Authors:  Catharine A Street; Brad A Bryan
Journal:  Anticancer Res       Date:  2011-11       Impact factor: 2.480

Review 4.  Rho kinase as a therapeutic target in cardiovascular disease.

Authors:  Michelle Surma; Lei Wei; Jianjian Shi
Journal:  Future Cardiol       Date:  2011-09

5.  RhoA protects the mouse heart against ischemia/reperfusion injury.

Authors:  Sunny Yang Xiang; Davy Vanhoutte; Dominic P Del Re; Nicole H Purcell; Haiyun Ling; Indroneal Banerjee; Julie Bossuyt; Richard A Lang; Yi Zheng; Scot J Matkovich; Shigeki Miyamoto; Jeffery D Molkentin; Gerald W Dorn; Joan Heller Brown
Journal:  J Clin Invest       Date:  2011-07-11       Impact factor: 14.808

6.  RhoA signaling in cardiomyocytes protects against stress-induced heart failure but facilitates cardiac fibrosis.

Authors:  Jessica Lauriol; Kimberly Keith; Fabrice Jaffré; Anthony Couvillon; Abdel Saci; Sanjeewa A Goonasekera; Jason R McCarthy; Chase W Kessinger; Jianxun Wang; Qingen Ke; Peter M Kang; Jeffery D Molkentin; Christopher Carpenter; Maria I Kontaridis
Journal:  Sci Signal       Date:  2014-10-21       Impact factor: 8.192

7.  Urotensin-#receptor antagonist SB-706375 protected isolated rat heart from ischaemia-reperfusion injury by attenuating myocardial necrosis via RhoA/ROCK/RIP3 signalling pathway.

Authors:  Jing-Si Duan; Shuo Chen; Xiao-Qing Sun; Juan Du; Zhi-Wu Chen
Journal:  Inflammopharmacology       Date:  2019-06-05       Impact factor: 4.473

Review 8.  The actin-MRTF-SRF gene regulatory axis and myofibroblast differentiation.

Authors:  Eric M Small
Journal:  J Cardiovasc Transl Res       Date:  2012-08-17       Impact factor: 4.132

9.  Rho-kinase inhibitor, fasudil, prevents neuronal apoptosis via the Akt activation and PTEN inactivation in the ischemic penumbra of rat brain.

Authors:  Jianhua Wu; Jianzhe Li; Hankun Hu; Ping Liu; Yunxiang Fang; Dongfang Wu
Journal:  Cell Mol Neurobiol       Date:  2012-05-03       Impact factor: 5.046

10.  The Rho kinase inhibitor, fasudil, ameliorates diabetes-induced cardiac dysfunction by improving calcium clearance and actin remodeling.

Authors:  Dongwu Lai; Jing Gao; Xukun Bi; Hong He; Xiaolu Shi; Shaoxiang Weng; Yu Chen; Ying Yang; Yang Ye; Guosheng Fu
Journal:  J Mol Med (Berl)       Date:  2016-08-30       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.